Bionano Genomics Inc (BNGO) Stock Price, Quote & News

Company Profile

Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, China, Japan, South Korea, Singapore, India, and Australia. The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It also provides Saphyr and Stratys systems, which are sample-to-resu...

Industry: Medical Instruments & Supplies

Sector: Healthcare

Phone: 858 888 7600

Website: bionano.com

Address:

9540 Towne Centre Drive, Suite 100, San Diego, United States

TheBioPunkRevenger Sep. 13 at 8:10 PM

$BNGO The modeling error is the whole trade. Fair value just ticked $5 → $6. They ran BNGO as a normal microcap kit company: no paid code, no utilization loop, cheap-for-a-reason. That model cannot hold 81195 at $1,853.22, Q2 chips +27% with demand still ahead of the factory, NYSDOH OGM LDTs, and a MolDX draft that says one genome-wide SV assay can replace banding + FISH + CMA. So the tape sits ~$1.22 while the assay is already in clinic. Wrong distribution. Wrong multiple. SWS moving $5 to $6 is the spreadsheet flinching — cheaper discount rate on the same name. McCarthy left Buy / $4 on. First tick, not the destination. They priced a science project. The maps were already running. $6 is the model starting to admit it.

0 · Reply

TheBioPunkRevenger Sep. 13 at 1:15 PM

$BNGO Maxim’s McCarthy reiterated Buy Sept 10. Target $4. Tape ~$1.22. That’s the Street number sitting on a washout multiple while the flywheel is already turning: live 81195 at $1,853.22, Q2 flow cells +27%, demand still ahead of chips, NYSDOH OGM LDTs in New York, MolDX proposed LCD for genome-wide SVs in heme — one assay vs banding + FISH + CMA. He didn’t walk it back to Hold. Coverage stayed Buy after the $1.00 print. $4 is not the ceiling. It’s the official admit the tape is still wrong. The map doesn’t need the rating. The rating finally caught a piece of the map.

0 · Reply

TheBioPunkRevenger Sep. 12 at 12:08 AM

$BNGO X banned me. Stocktwits banned me before. Tonight Reddit banned r/OGM_BionanoGenomics — hammer page, community gone. That’s the pattern if you talk this name like it matters. Not a quiet mute. The rooms themselves get shut. 81195 is still live. MolDX still has a proposed LCD on genome-wide SVs in heme. NYSDOH still cleared OGM LDTs in New York. Q2 chips still printed +27%. Luderer still doubled 4k → 8k. The assay didn’t get banned. The places that said it out loud did.

0 · Reply

BioTuesdays Sep. 11 at 2:03 AM

Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics $BNGO has announced that MolDX, a program that assesses molecular diagnostic technologies on behalf of Medicare Administrative Contractors (MACs), has issued a proposed Local Coverage Determination (LCD) for Genome-Wide Molecular Methodologies for the Detection of Copy Number Alterations and Structural Variants in Hematologic Neoplasms. https://biotuesdays.com/2026/09/10/moldx-issues-bionano-proposed-lcd/

0 · Reply

focafoca99 Sep. 10 at 9:52 PM

$BNGO outlined a proposed Medicare LCD that would cover its OGM-Dx test for hematologic malignancies. https://www.rapidticker.com/news/bngo-bionano-laboratories-announces-proposed-local-7ad478

0 · Reply

TheBioPunkRevenger Sep. 10 at 1:34 PM

$BNGO MolDX proposed an LCD for genome-wide structural variants and copy-number changes in heme cancers. OGM sits in that bucket. Public comment through Oct 11. The line that matters: one assay can deliver equivalent or greater clinically useful information than banding + FISH + CMA stacked. That’s Medicare’s contractor writing the flywheel in policy language. Scope in the draft: leukemia, lymphoma, myeloma — diagnosis, progression, relapse — when guidelines say it changes management. OGM-Dx HemeOne is what Bionano Labs says belongs under it after the LCD is final and they pass technical assessment. 81195 is already the Category I rate. The LCD is how MACs stop treating the claim like optional research. Proposed ≠ paid. Final + TA still required. This is still the biggest Medicare-policy print OGM has gotten on heme. Tape can ignore a draft. The flywheel doesn’t. https://ir.bionanogenomics.com/news-releases/news-release-details/bionano-laboratories-announces-proposed-local-coverage

0 · Reply

TheBioPunkRevenger Sep. 10 at 1:11 PM

$BNGO Interim CEO Luderer doubled down: IRA common: 4,000 → 8,000. 21 Aug — 4,000 @ ~$1.22. Open market. 4 Sep — another 4,000 @ $1.2112. Same Traditional IRA. Filed 9 Sep. Cash. Not a vest. Not options hitting the account. He bought a ticket, then copied it two weeks later. That sits on the $1.00 wash, Q2 flow cells +27%, and live 81195. NYSDOH also just opened OGM LDTs in New York. The multiple still treats OGM like a science project. The interim CEO just told you, twice, he doesn’t. REPEATING the same buy is the tell.

0 · Reply

TheBioPunkRevenger Sep. 8 at 3:52 PM

$BNGO NYSDOH just cleared OGM LDTs at URochester — reproductive disorders and hematologic malignancies. First time New York patients can get that map in the clinic. New York CLEP is the filter most LDTs fail. A cancer-center lab (Iqbal / Wilmot) now has state approval to run OGM for heme and genetic-disorder workups. Genome-wide structural variants in one workflow instead of a pile of banding/FISH. Hastie called it a milestone for tests Bionano Laboratories offers and has in the pipeline. Direct observation of native ultra-long DNA. 81195 already live. The map just entered a regulated clinical door in the toughest state. Tape still prices the assay like that door didn’t open. https://ir.bionanogenomics.com/news-releases/news-release-details/bionano-laboratories-announces-new-york-state-department-health

0 · Reply

focafoca99 Sep. 8 at 1:40 PM

$BNGO obtains New York State Department of Health approval for its optical genome mapping clinical tests. https://www.rapidticker.com/news/bngo-bionano-laboratories-announces-new-york-c15961

0 · Reply

janed102 Sep. 5 at 11:52 PM

$BNGO ..... reading https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2026.1861975/full

1 · Reply

Market Cap	14.37M
Revenue (ttm)	28.51M
Net Income (ttm)	-26.40M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-92.60%
Debt to Equity Ratio	0.00

Volume	57,900
Avg Vol	134,700
Day's Range	N/A - N/A
Shares Out	11.78M
Stochastic %K	54%
Beta	1.65
Analysts	Strong Sell
Price Target	$5.00